- Zai Lab’s second-quarter revenue amounted to $110.0 million, marking a 9.4% increase compared to the previous year.
- The reported revenue fell short of the estimated $125.5 million.
- Operating loss for the second quarter was $54.9 million, reflecting a 28% decrease from last year.
- The operating loss was higher than the estimated loss of $45.2 million.
- Zai Lab’s stock analysis includes 12 buy recommendations, 1 hold, and no sell recommendations.
A look at Zai Lab Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Zai Lab Ltd, a bio-pharmaceutical company, shows promising long-term potential according to Smartkarma Smart Scores. With a strong score of 5 for Growth, Zai Lab demonstrates impressive potential for expansion and development in the future. Additionally, the company scores 3 on both Resilience and Momentum, indicating a solid foundation and steady progress in the market. While Value and Dividend scores are lower at 2 and 1 respectively, the high Growth score suggests Zai Lab’s focus on advancing its therapeutic technologies for various diseases, including oncology and autoimmune conditions, bodes well for its future growth.
Specializing in antibody-based treatments for oncology, autoimmune, and infectious diseases, Zai Lab Ltd is positioned to thrive in the healthcare sector. The company’s diversified drug manufacturing capabilities, offering capsules, injections, and liquids, cater to a global patient base. With a strong emphasis on growth and innovation, Zai Lab’s high Growth score reflects its commitment to advancing treatment options for patients worldwide. As the company continues to focus on research and development in the bio-pharmaceutical space, investors may find Zai Lab’s long-term outlook appealing amid ongoing market dynamics.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
